Amarin Corp Plcuk (AMRN) Cash & Equivalents (2010 - 2026)
Amarin Corp Plcuk (AMRN) posted quarterly Cash & Equivalents of $201000.0 for Q1 2026, down 33.0% YoY from $300000.0 in Q1 2025, and down 99.85% sequentially from $134.7 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Cash & Equivalents (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk has disclosed Cash & Equivalents across 17 years of filings, most recently posting $201000.0 for Q1 2026.
- In Q1 2026, Cash & Equivalents fell 33.0% year-over-year to $201000.0; the TTM figure through Mar 2026 stood at $201000.0 (down 33.0% YoY), while the FY2025 annual figure was $134.7 million, up 44786.67% from the prior year.
- Cash & Equivalents slipped to $201000.0 in Q1 2026, from $134.7 million in the prior quarter.
- Over the last five years, Cash & Equivalents for AMRN reached as high as $228.0 million in Q2 2022 and fell as low as $201000.0 in Q1 2026.
- The 5-year median for Cash & Equivalents is $525000.0 (2023), against an average of $76.6 million.
- The widest YoY moves for Cash & Equivalents: up 44786.67% in 2025, down 99.81% in 2025.
- A 5-year view of Cash & Equivalents shows it stood at $523000.0 in 2022, then advanced by 0.38% to $525000.0 in 2023, then sank by 42.86% to $300000.0 in 2024, then surged by 44786.67% to $134.7 million in 2025, then tumbled by 99.85% to $201000.0 in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $201000.0, $134.7 million, and $301000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 21.69 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 9.39 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 7.56 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | 201,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 201,000.00 |
| Dec 31, 2025 | 134.66 Mn |
| Sep 30, 2025 | 301,000.00 |
| Jun 30, 2025 | 147.90 Mn |
| Mar 31, 2025 | 300,000.00 |
| Dec 31, 2024 | 300,000.00 |
| Sep 30, 2024 | 156.90 Mn |
| Jun 30, 2024 | 215.90 Mn |
| Mar 31, 2024 | 525,000.00 |
| Dec 31, 2023 | 525,000.00 |
| Sep 30, 2023 | 524,000.00 |
| Jun 30, 2023 | 524,000.00 |
| Mar 31, 2023 | 191.41 Mn |
| Dec 31, 2022 | 523,000.00 |
| Sep 30, 2022 | 3.92 Mn |
| Jun 30, 2022 | 228.00 Mn |
| Mar 31, 2022 | 219.20 Mn |
| Dec 31, 2021 | 219.45 Mn |
| Sep 30, 2021 | 222.90 Mn |
| Jun 30, 2021 | 3.92 Mn |